PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34778972-1 2021 beta-caryophyllene (BCP), a natural sesquiterpene present in plants, is a selective agonist of cannabinoid receptor type-2 (CB2) of the endocannabinoid system. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 95-122 34778972-20 2021 The findings from this study strongly suggest the beneficial neuroactive properties of black pepper seed extract having the presence of BCP, a CB2 receptor agonist. caryophyllene 136-139 cannabinoid receptor 2 (macrophage) Mus musculus 143-146 34778972-1 2021 beta-caryophyllene (BCP), a natural sesquiterpene present in plants, is a selective agonist of cannabinoid receptor type-2 (CB2) of the endocannabinoid system. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 124-127 34778972-1 2021 beta-caryophyllene (BCP), a natural sesquiterpene present in plants, is a selective agonist of cannabinoid receptor type-2 (CB2) of the endocannabinoid system. caryophyllene 20-23 cannabinoid receptor 2 (macrophage) Mus musculus 95-122 34778972-1 2021 beta-caryophyllene (BCP), a natural sesquiterpene present in plants, is a selective agonist of cannabinoid receptor type-2 (CB2) of the endocannabinoid system. caryophyllene 20-23 cannabinoid receptor 2 (macrophage) Mus musculus 124-127 34846548-10 2022 The potency of beta-caryophyllene to reverse mechanical allodynia decreased 1.80-fold in CB2R (-/-) mice. caryophyllene 15-33 cannabinoid receptor 2 (macrophage) Mus musculus 89-93 34566647-0 2021 beta-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 134-137 34566647-0 2021 beta-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 146-149 34566647-6 2021 Genetic deletion of CB2 receptors in CB2-knockout (CB2-KO) mice also blocked low dose BCP-induced reduction in METH self-administration, suggesting possible involvement of a CB2 receptor mechanism. caryophyllene 86-89 cannabinoid receptor 2 (macrophage) Mus musculus 20-23 34566647-6 2021 Genetic deletion of CB2 receptors in CB2-knockout (CB2-KO) mice also blocked low dose BCP-induced reduction in METH self-administration, suggesting possible involvement of a CB2 receptor mechanism. caryophyllene 86-89 cannabinoid receptor 2 (macrophage) Mus musculus 37-40 34566647-6 2021 Genetic deletion of CB2 receptors in CB2-knockout (CB2-KO) mice also blocked low dose BCP-induced reduction in METH self-administration, suggesting possible involvement of a CB2 receptor mechanism. caryophyllene 86-89 cannabinoid receptor 2 (macrophage) Mus musculus 51-54 34566647-7 2021 However, at high doses, BCP produced a reduction in METH self-administration in CB2-KO mice in a manner similar as in WT mice, suggesting that non-CB2 receptor mechanisms underlie high dose BCP-produced effects. caryophyllene 24-27 cannabinoid receptor 2 (macrophage) Mus musculus 147-150 31841509-2 2019 Recently, it was found that beta-caryophyllene is a ligand of the cannabinoid receptor 2 (CB2). caryophyllene 28-46 cannabinoid receptor 2 (macrophage) Mus musculus 66-88 31892132-7 2019 A CB2 receptor antagonist (AM 630), but not a CB1 receptor antagonist (AM 251), antagonized BCP attenuation of established ddC-induced mechanical allodynia. caryophyllene 92-95 cannabinoid receptor 2 (macrophage) Mus musculus 2-5 34277815-2 2021 We aimed to investigate the mechanism of the CNR2 agonist (beta-caryophyllene, beta-Car) in regulating the balance of regulatory T cells (Treg) and T helper cell 17 (Th17) and thus its role in asthma. caryophyllene 59-77 cannabinoid receptor 2 (macrophage) Mus musculus 45-49 35092394-12 2022 CNR2 was the notable target of beta-caryophyllene and performed agonistic interaction, which might have contributed to its cytotoxic activity against 4T1 cells. caryophyllene 31-49 cannabinoid receptor 2 (macrophage) Mus musculus 0-4 31883107-2 2020 Recent studies indicate that BCP is a cannabinoid CB2 receptor (CB2R) agonist with medical benefits for a number of human diseases. caryophyllene 29-32 cannabinoid receptor 2 (macrophage) Mus musculus 50-53 31883107-2 2020 Recent studies indicate that BCP is a cannabinoid CB2 receptor (CB2R) agonist with medical benefits for a number of human diseases. caryophyllene 29-32 cannabinoid receptor 2 (macrophage) Mus musculus 64-68 31883107-7 2020 Genetic deletion of CB2Rs in CB2-knockout mice blocked the reduction in nicotine self-administration produced only by low doses, but not high doses, of BCP, suggesting the involvement of both CB2 and non-CB2 receptor mechanisms. caryophyllene 152-155 cannabinoid receptor 2 (macrophage) Mus musculus 20-23 31883107-7 2020 Genetic deletion of CB2Rs in CB2-knockout mice blocked the reduction in nicotine self-administration produced only by low doses, but not high doses, of BCP, suggesting the involvement of both CB2 and non-CB2 receptor mechanisms. caryophyllene 152-155 cannabinoid receptor 2 (macrophage) Mus musculus 29-32 31883107-7 2020 Genetic deletion of CB2Rs in CB2-knockout mice blocked the reduction in nicotine self-administration produced only by low doses, but not high doses, of BCP, suggesting the involvement of both CB2 and non-CB2 receptor mechanisms. caryophyllene 152-155 cannabinoid receptor 2 (macrophage) Mus musculus 29-32 31883107-10 2020 CONCLUSIONS AND IMPLICATIONS: The present findings suggest that BCP has significant anti-nicotine effects via both CB2 and non-CB2 receptor mechanisms, and therefore, deserves further study as a potential new pharmacotherapy for cigarette smoking cessation. caryophyllene 64-67 cannabinoid receptor 2 (macrophage) Mus musculus 115-118 31883107-10 2020 CONCLUSIONS AND IMPLICATIONS: The present findings suggest that BCP has significant anti-nicotine effects via both CB2 and non-CB2 receptor mechanisms, and therefore, deserves further study as a potential new pharmacotherapy for cigarette smoking cessation. caryophyllene 64-67 cannabinoid receptor 2 (macrophage) Mus musculus 127-139 31841509-2 2019 Recently, it was found that beta-caryophyllene is a ligand of the cannabinoid receptor 2 (CB2). caryophyllene 28-46 cannabinoid receptor 2 (macrophage) Mus musculus 90-93 24999220-0 2014 The cannabinoid receptor 2 agonist, beta-caryophyllene, reduced voluntary alcohol intake and attenuated ethanol-induced place preference and sensitivity in mice. caryophyllene 36-54 cannabinoid receptor 2 (macrophage) Mus musculus 4-26 31711937-2 2019 beta-Caryophyllene (BCP), a natural and selective CB2 agonist, possesses several protective effects. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 50-53 31711937-2 2019 beta-Caryophyllene (BCP), a natural and selective CB2 agonist, possesses several protective effects. caryophyllene 20-23 cannabinoid receptor 2 (macrophage) Mus musculus 50-53 31173795-0 2019 The cannabinoid receptor 2 agonist, beta-caryophyllene, improves working memory and reduces circulating levels of specific proinflammatory cytokines in aged male mice. caryophyllene 36-54 cannabinoid receptor 2 (macrophage) Mus musculus 4-26 28107775-8 2018 These protective effects of BCP against alcohol-induced liver injury were attenuated in CB2 receptor knockout mice, indicating that the beneficial effects of this natural product in liver injury involve activation of these receptors. caryophyllene 28-31 cannabinoid receptor 2 (macrophage) Mus musculus 88-91 28026135-6 2017 TC has been shown to be an agonist of the cannabinoid type 2 receptor (CB2R), and the effects of TC on osteocalcin secretion and matrix mineralization were abolished in MC3T3E1 cells transfected with CB2R siRNA. caryophyllene 0-2 cannabinoid receptor 2 (macrophage) Mus musculus 42-69 28026135-6 2017 TC has been shown to be an agonist of the cannabinoid type 2 receptor (CB2R), and the effects of TC on osteocalcin secretion and matrix mineralization were abolished in MC3T3E1 cells transfected with CB2R siRNA. caryophyllene 0-2 cannabinoid receptor 2 (macrophage) Mus musculus 71-75 28026135-6 2017 TC has been shown to be an agonist of the cannabinoid type 2 receptor (CB2R), and the effects of TC on osteocalcin secretion and matrix mineralization were abolished in MC3T3E1 cells transfected with CB2R siRNA. caryophyllene 0-2 cannabinoid receptor 2 (macrophage) Mus musculus 200-204 28026135-6 2017 TC has been shown to be an agonist of the cannabinoid type 2 receptor (CB2R), and the effects of TC on osteocalcin secretion and matrix mineralization were abolished in MC3T3E1 cells transfected with CB2R siRNA. caryophyllene 97-99 cannabinoid receptor 2 (macrophage) Mus musculus 200-204 28026135-7 2017 Our findings that TC promotes the formation of a mineralized extracellular matrix help to elucidate the role of CB2 signaling in the formation of bone and the maintenance of normal bone mass. caryophyllene 18-20 cannabinoid receptor 2 (macrophage) Mus musculus 112-115 31766439-8 2019 Based on our findings, we believe that CB2R activation may represent a viable therapeutic target for IC, and that drugs that activate CB2R, such as the generally regarded as safe (GRAS) dietary sesquiterpenoid, BCP, may serve as an adjunct and/or alternative treatment option for alleviating symptoms of inflammation and pain in the management of IC. caryophyllene 211-214 cannabinoid receptor 2 (macrophage) Mus musculus 134-138 31370242-0 2019 beta-Caryophyllene Mitigates Collagen Antibody Induced Arthritis (CAIA) in Mice Through a Cross-Talk between CB2 and PPAR-gamma Receptors. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 109-112 31370242-1 2019 beta-caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that tempers inflammation. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 30-52 31370242-1 2019 beta-caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that tempers inflammation. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 54-57 31370242-1 2019 beta-caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that tempers inflammation. caryophyllene 20-23 cannabinoid receptor 2 (macrophage) Mus musculus 30-52 31370242-1 2019 beta-caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that tempers inflammation. caryophyllene 20-23 cannabinoid receptor 2 (macrophage) Mus musculus 54-57 31370242-12 2019 These results suggest that BCP ameliorates arthritis through a cross-talk between CB2 and PPAR-gamma. caryophyllene 27-30 cannabinoid receptor 2 (macrophage) Mus musculus 82-85 29547827-0 2018 Pharmacological characterization of the cannabinoid receptor 2 agonist, beta-caryophyllene on seizure models in mice. caryophyllene 72-90 cannabinoid receptor 2 (macrophage) Mus musculus 40-62 29547827-3 2018 The aim of the present study was to explore the effect of a selective CB2 receptor agonist beta-caryophyllene (BCP) in models of seizures and cognition in mice. caryophyllene 91-109 cannabinoid receptor 2 (macrophage) Mus musculus 70-73 29547827-3 2018 The aim of the present study was to explore the effect of a selective CB2 receptor agonist beta-caryophyllene (BCP) in models of seizures and cognition in mice. caryophyllene 111-114 cannabinoid receptor 2 (macrophage) Mus musculus 70-73 28729222-9 2017 BCP attenuated the established mechanical allodynia induced by PTX (p < 0.0001) in a CB2-dependent manner. caryophyllene 0-3 cannabinoid receptor 2 (macrophage) Mus musculus 88-91 28729222-12 2017 Our findings show that BCP effectively attenuated PINP, possibly through CB2-activation in the CNS and posterior inhibition of p38 MAPK/NF-kappaB activation and cytokine release. caryophyllene 23-26 cannabinoid receptor 2 (macrophage) Mus musculus 73-76 28684694-4 2017 beta-caryophyllene (BCP) is a natural bicyclic sesquiterpene that is an agonist of the cannabinoid type 2 receptor (CB2R). caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 87-114 28684694-4 2017 beta-caryophyllene (BCP) is a natural bicyclic sesquiterpene that is an agonist of the cannabinoid type 2 receptor (CB2R). caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 116-120 28684694-4 2017 beta-caryophyllene (BCP) is a natural bicyclic sesquiterpene that is an agonist of the cannabinoid type 2 receptor (CB2R). caryophyllene 20-23 cannabinoid receptor 2 (macrophage) Mus musculus 87-114 28684694-4 2017 beta-caryophyllene (BCP) is a natural bicyclic sesquiterpene that is an agonist of the cannabinoid type 2 receptor (CB2R). caryophyllene 20-23 cannabinoid receptor 2 (macrophage) Mus musculus 116-120 28368293-0 2017 (-)-beta-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis. caryophyllene 0-22 cannabinoid receptor 2 (macrophage) Mus musculus 26-29 28368293-1 2017 (-)-beta-caryophyllene (BCP), a cannabinoid receptor type 2 (CB2)-selective phytocannabinoid, has already been shown in precedent literature to exhibit both anti-inflammatory and analgesic effects in mouse models of inflammatory and neuropathic pain. caryophyllene 0-22 cannabinoid receptor 2 (macrophage) Mus musculus 61-64 28368293-1 2017 (-)-beta-caryophyllene (BCP), a cannabinoid receptor type 2 (CB2)-selective phytocannabinoid, has already been shown in precedent literature to exhibit both anti-inflammatory and analgesic effects in mouse models of inflammatory and neuropathic pain. caryophyllene 24-27 cannabinoid receptor 2 (macrophage) Mus musculus 61-64 24999220-3 2014 The CB2 receptor agonist, beta-caryophyllene (BCP) was used to investigate the role of the CB2 receptors in mediating alcohol intake and ethanol-induced conditioned place preference (EtOH-CPP) and sensitivity in mice. caryophyllene 26-44 cannabinoid receptor 2 (macrophage) Mus musculus 4-7 24999220-3 2014 The CB2 receptor agonist, beta-caryophyllene (BCP) was used to investigate the role of the CB2 receptors in mediating alcohol intake and ethanol-induced conditioned place preference (EtOH-CPP) and sensitivity in mice. caryophyllene 46-49 cannabinoid receptor 2 (macrophage) Mus musculus 4-7 24930711-0 2014 beta-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 22-25 24930711-2 2014 The aim of the current experiments was to test the effects of the CB2 receptor potent-selective agonist beta-caryophyllene (BCP) in animals subjected to models of anxiolytic- and antidepressant-like effects. caryophyllene 104-122 cannabinoid receptor 2 (macrophage) Mus musculus 66-69 24930711-2 2014 The aim of the current experiments was to test the effects of the CB2 receptor potent-selective agonist beta-caryophyllene (BCP) in animals subjected to models of anxiolytic- and antidepressant-like effects. caryophyllene 124-127 cannabinoid receptor 2 (macrophage) Mus musculus 66-69 24930711-10 2014 Most importantly, pre-administration of the CB2 receptor antagonist AM630, fully abrogated the anxiolytic and the anti-depressant effects of BCP. caryophyllene 141-144 cannabinoid receptor 2 (macrophage) Mus musculus 44-47 24210682-0 2014 The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. caryophyllene 56-74 cannabinoid receptor 2 (macrophage) Mus musculus 16-19 24486541-2 2014 Trans-caryophyllene (TC), an important constituent of the essential oil of several species of plants, has been reported to activate the type 2 cannabinoid receptor (CB2R). caryophyllene 0-19 cannabinoid receptor 2 (macrophage) Mus musculus 165-168 24486541-2 2014 Trans-caryophyllene (TC), an important constituent of the essential oil of several species of plants, has been reported to activate the type 2 cannabinoid receptor (CB2R). caryophyllene 21-23 cannabinoid receptor 2 (macrophage) Mus musculus 165-168 24486541-5 2014 However, inhibition of CB2R by a specific inhibitor or specific RNA interference abolished the effects of TC on GSIS, which suggests that the effects of TC on GSIS are dependent on activation of CB2R. caryophyllene 106-108 cannabinoid receptor 2 (macrophage) Mus musculus 23-27 24486541-5 2014 However, inhibition of CB2R by a specific inhibitor or specific RNA interference abolished the effects of TC on GSIS, which suggests that the effects of TC on GSIS are dependent on activation of CB2R. caryophyllene 106-108 cannabinoid receptor 2 (macrophage) Mus musculus 195-199 24486541-5 2014 However, inhibition of CB2R by a specific inhibitor or specific RNA interference abolished the effects of TC on GSIS, which suggests that the effects of TC on GSIS are dependent on activation of CB2R. caryophyllene 153-155 cannabinoid receptor 2 (macrophage) Mus musculus 23-27 24486541-5 2014 However, inhibition of CB2R by a specific inhibitor or specific RNA interference abolished the effects of TC on GSIS, which suggests that the effects of TC on GSIS are dependent on activation of CB2R. caryophyllene 153-155 cannabinoid receptor 2 (macrophage) Mus musculus 195-199 21356367-0 2011 beta-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARgamma pathway. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 83-86 23138934-12 2013 The antinociceptive effect produced by BCP was prevented by pretreatment with AM630, a selective CB2 receptor antagonist, but not by AM251, a selective CB1 receptor antagonist. caryophyllene 39-42 cannabinoid receptor 2 (macrophage) Mus musculus 97-100 23138934-18 2013 BCP is mediated by activation of CB2 receptors, which stimulates the local release from keratinocytes of the endogenous opioid beta-endorphin. caryophyllene 0-3 cannabinoid receptor 2 (macrophage) Mus musculus 33-36 21356367-7 2011 The use of the CB2 antagonist AM630 or the PPARgamma antagonist GW9662 significantly reversed the protective effect of BCP. caryophyllene 119-122 cannabinoid receptor 2 (macrophage) Mus musculus 15-18 21356367-9 2011 These results demonstrate that the anti-inflammatory effect of BCP involves CB2 and the PPARgamma pathway and suggest BCP as a possible therapy for the treatment of inflammatory bowel disease. caryophyllene 63-66 cannabinoid receptor 2 (macrophage) Mus musculus 76-79 25171128-0 2014 beta-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARgamma pathway. caryophyllene 0-18 cannabinoid receptor 2 (macrophage) Mus musculus 84-87 25171128-2 2014 Recently, the plant metabolite beta-caryophyllene was shown to selectively bind to CB2 receptor and act as a full agonist. caryophyllene 31-49 cannabinoid receptor 2 (macrophage) Mus musculus 83-86 25171128-6 2014 The use of the CB2 antagonist AM630 or the PPARgamma antagonist GW9662 significantly reversed the protective effects of beta-caryophyllene on APP/PS1 mice. caryophyllene 120-138 cannabinoid receptor 2 (macrophage) Mus musculus 15-18 25171128-7 2014 CONCLUSION: These results demonstrate that the anti-inflammatory effect of the sesquiterpene beta-caryophyllene involves CB2 receptor activation and the PPARgamma pathway and suggest beta-caryophyllene as an attractive molecule for the development of new drugs with therapeutic potential for the treatment of AD. caryophyllene 93-111 cannabinoid receptor 2 (macrophage) Mus musculus 121-124 21356367-2 2011 Recently, the plant metabolite (E)-beta-caryophyllene (BCP) was shown to bind to and activate CB2. caryophyllene 31-53 cannabinoid receptor 2 (macrophage) Mus musculus 94-97 21356367-2 2011 Recently, the plant metabolite (E)-beta-caryophyllene (BCP) was shown to bind to and activate CB2. caryophyllene 55-58 cannabinoid receptor 2 (macrophage) Mus musculus 94-97